Tag: paroxetine
Psychiatry’s Thalidomide Moment
The authors of Study 329 began recruiting adolescents for a comparative study of Paxil, imipramine and placebo in 1994 and finished their investigations in 1997. They dropped a large number of their original cohort, so the randomness element in the study must be open to question. Late in 1998, SmithKline Beecham, the marketers of Paxil, acknowledged in an internal document that the study had shown that Paxil didnāt work for adolescents in terms of the two primary and six secondary outcomes they had established at the start of the study. In a nutshell, Study 329 was negative for efficacy and positive for harm, contrary to their succinct upbeat conclusion.
The Troubled Life of Study 329: Consequences of Failure to Retract
If someone were to ask the surviving authors of Study 329 the question: āKnowing what you know now, if you had to do it over, would you agree to participate in that study again?ā, many would probably say no. Study 329ās problems started to surface right after it was published. Several doctors wrote letters to the JAACAP Editor with probing questions, mostly centred on the psychiatric side effects of paroxetine, and the measures used to claim its efficacy in treating adolescents. The authors responded and the questioners did not pursue their concerns further. Except one.
Next week, fourteen years and two months after it was published, it is about to take yet another hit, when the Restored version is published.